Search Results - "drug development"

Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool by Juan Francisco Morales, Marian Klose, Yannick Hoffert, Jagdeep T. Podichetty, Jackson Burton, Stephan Schmidt, Klaus Romero, Inish O'Doherty, Frank Martin, Martha Campbell‐Thompson, Michael J. Haller, Mark A. Atkinson, Sarah Kim

Connect to this object online.

Nuclear Receptors as Targets for Drug Development: The Role of Nuclear Receptors During Neural Stem Cell Proliferation and Differentiation by Kazufumi Katayama, Koichiro Wada, Atsushi Nakajima, Yoshinori Kamisaki, Tadanori Mayumi

Connect to this object online.

US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development by Anne Vinther Morant, Henrik Tang Vestergaard, Anders Blædel Lassen, Vaidrius Navikas

Connect to this object online.

Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches? by Songmao Zheng, Rodney Prell, Jennifer Sheng, Yow‐Ming Wang, Lora Hamuro

Connect to this object online.

Exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development by Han S, Jeon S, Hong T, Lee J, Bae SH, Park WS, Park G, Youn S, Jang DY, Kim KS, Yim DS

Connect to this object online.

Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare by Lara Marques, Bárbara Costa, Mariana Pereira, Abigail Silva, Joana Santos, Leonor Saldanha, Isabel Silva, Paulo Magalhães, Stephan Schmidt, Nuno Vale

Connect to this object online.

Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development by Joseph Kotsybar, Susan Hakeem, Lei Zhang, Wenlei Jiang

Connect to this object online.

Progress in the search for blood substitutes, part 1 Preparations currently used in haemotherapy as an indicator of new drug development by Waldemar Grzegorzewski, Ewa Mil, Katarzyna Gołda, Anna Czarniecka-Kubicka, Łukasz Puchała

Connect to this object online.

Application of the <i>AlphaScreen</i> and <i>AlphaLisa</i> method in drug development and pharmacokinetic studies by R. T. Mukhametshina, S. D. Kopein, V. M. Simonov

Connect to this object online.

Public-Private Partnerships as drivers of innovation in healthcare

Subjects: “…Drug Development…”
DOAB: download the publication
DOAB: description of the publication

Public-Private Partnerships as Drivers of Innovation in Healthcare, 2nd Edition

Subjects: “…Drug Development…”
DOAB: download the publication
DOAB: description of the publication

Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma by Joanna C. Masters, Akash Khandelwal, Alessandra diPietro, Haiqing Dai, Satjit Brar

Connect to this object online.

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development by Susan Reijntjes, Muna Albayaty, James Bush, Joseph Cheriyan, Anthea Cromie, Annelize Koch, Michael Hammond, Stuart Mair, Peter Scholes, Ulrike Lorch, Steffan Stringer, Jorg Taubel, Timothy C. Hardman

Connect to this object online.

Differential representation of liver proteins in obese human subjects suggests novel biomarkers and promising targets for drug development in obesity by Simonetta Caira, Antonio Iannelli, Rosaria Sciarrillo, Gianluca Picariello, Giovanni Renzone, Andrea Scaloni, Pietro Addeo

Connect to this object online.

Study design considerations to assess the impact of potential drug-drug interactions in first‐in‐human studies in oncology drug development by Sriram Subramaniam, Stacy S. Shord, Ruby Leong, Kelly Norsworthy, Atiqur Rahman, Brian Booth, Olanrewaju Okusanya

Connect to this object online.

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development by Etelka Pöstyéni, Róbert Gábriel, Andrea Kovács-Valasek

Connect to this object online.

Simulation‐based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development by Zrinka Duvnjak, Franziska Schaedeli Stark, Valérie Cosson, Sylvie Retout, Emilie Schindler, João A. Abrantes

Connect to this object online.

Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review by Klaudia T. Angula, Lesetja J. Legoabe, Richard M. Beteck

Connect to this object online.

Exploring the Multi-Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer's Disease by Jaime R. Cabrera-Pardo, Jaime R. Cabrera-Pardo, Jaime R. Cabrera-Pardo, Jorge Fuentealba, Javiera Gavilán, Daniel Cajas, José Becerra, Mariola Napiórkowska

Connect to this object online.

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor by Daryl J. Fediuk, Gianluca Nucci, Vikas K. Dawra, Ernesto Callegari, Susan Zhou, Cynthia J. Musante, Yali Liang, Kevin Sweeney, Vaishali Sahasrabudhe

Connect to this object online.